Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SYS6006 alone or with enlonstobart injection in advanced solid tumors
CTR20261608Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Apr 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of SYS6006 in Nonhematologic neoplasms (2 arms), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 5 more. Started Apr 2026; status: active.
02
Drugs
SYS6006
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20261608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261608.